464 related articles for article (PubMed ID: 26494382)
1. Thyroid C-Cell Biology and Oncogenic Transformation.
Cote GJ; Grubbs EG; Hofmann MC
Recent Results Cancer Res; 2015; 204():1-39. PubMed ID: 26494382
[TBL] [Abstract][Full Text] [Related]
2. Histopathology of C Cells and Medullary Thyroid Carcinoma.
Schmid KW
Recent Results Cancer Res; 2015; 204():41-60. PubMed ID: 26494383
[TBL] [Abstract][Full Text] [Related]
3. Selective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma.
Song H; Lin C; Yao E; Zhang K; Li X; Wu Q; Chuang PT
J Biol Chem; 2017 Mar; 292(9):3888-3899. PubMed ID: 28119454
[TBL] [Abstract][Full Text] [Related]
4. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
5. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K; Raue F
Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
[TBL] [Abstract][Full Text] [Related]
6. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
8. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
[TBL] [Abstract][Full Text] [Related]
9. Expression of Tenascin C, EGFR, E-Cadherin, and TTF-1 in Medullary Thyroid Carcinoma and the Correlation with RET Mutation Status.
Steiner F; Hauser-Kronberger C; Rendl G; Rodrigues M; Pirich C
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409604
[TBL] [Abstract][Full Text] [Related]
10. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
[TBL] [Abstract][Full Text] [Related]
11. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation.
Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037
[TBL] [Abstract][Full Text] [Related]
12. RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM; Cavaco BM; Leite V
Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
[TBL] [Abstract][Full Text] [Related]
13. [Thyroid C cells and their pathology: Part 1: normal C cells, - C cell hyperplasia, - precursor of familial medullary thyroid carcinoma].
Ting S; Synoracki S; Schmid KW
Pathologe; 2015 May; 36(3):246-53. PubMed ID: 25898937
[TBL] [Abstract][Full Text] [Related]
14. Mice conditionally expressing RET(C618F) mutation display C cell hyperplasia and hyperganglionosis of the enteric nervous system.
Okamoto M; Yoshioka Y; Maeda K; Bito Y; Fukumoto T; Uesaka T; Enomoto H
Genesis; 2019 May; 57(5):e23292. PubMed ID: 30884088
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
[TBL] [Abstract][Full Text] [Related]
16. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
Chu YH; Lloyd RV
Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
[TBL] [Abstract][Full Text] [Related]
17. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
18. Ret gene silencing is associated with Raf-1-induced medullary thyroid carcinoma cell differentiation.
Carson EB; McMahon M; Baylin SB; Nelkin BD
Cancer Res; 1995 May; 55(10):2048-52. PubMed ID: 7743500
[TBL] [Abstract][Full Text] [Related]
19. Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions.
Maliszewska A; Leandro-Garcia LJ; Castelblanco E; Macià A; de Cubas A; Goméz-López G; Inglada-Pérez L; Álvarez-Escolá C; De la Vega L; Letón R; Gómez-Graña Á; Landa I; Cascón A; Rodríguez-Antona C; Borrego S; Zane M; Schiavi F; Merante-Boschin I; Pelizzo MR; Pisano DG; Opocher G; Matias-Guiu X; Encinas M; Robledo M
Am J Pathol; 2013 Feb; 182(2):350-62. PubMed ID: 23201134
[TBL] [Abstract][Full Text] [Related]
20. Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma.
El Naofal M; Kim A; Yon HY; Baity M; Ming Z; Bui-Griffith J; Tang Z; Robinson M; Grubbs EG; Cote GJ; Hu P
Ann Clin Lab Sci; 2017 Sep; 47(5):523-528. PubMed ID: 29066476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
